Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations

被引:34
|
作者
Shen, Jie [1 ]
Lu, Guang Wei [2 ]
Hughes, Patrick [3 ]
机构
[1] Allergan Plc, Clin Pharmacol Nonclin & Translat Sci, 2525 Dupont Dr, Irvine, CA 92612 USA
[2] TWi Pharmaceut Inc, Ophthalm Prod Dev, Taipei, Taiwan
[3] Glaukos Corp, Appl Res, San Clemente, CA USA
关键词
formulation; ocular; pharmacokinetic; pharmacodynamic; sustained release; targeted delivery; EPISCLERAL CYCLOSPORINE IMPLANT; IN-VITRO; SUBCONJUNCTIVAL BEVACIZUMAB; SUSTAINED-RELEASE; VIVO EVALUATION; AQUEOUS-HUMOR; GLAUCOMA; PHARMACOKINETICS; LATANOPROST; ABSORPTION;
D O I
10.1007/s11095-018-2498-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations
    Jie Shen
    Guang Wei Lu
    Patrick Hughes
    Pharmaceutical Research, 2018, 35
  • [2] Pharmacokinetic considerations for targeted drug delivery
    Yamashita, Fumiyoshi
    Hashida, Mitsuru
    ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) : 139 - 147
  • [3] Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
    Ismail, Ayman
    Nasr, Maha
    Sammour, Omaima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 583
  • [4] Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution
    Takakura, Y
    Hashida, M
    PHARMACEUTICAL RESEARCH, 1996, 13 (06) : 820 - 831
  • [5] Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations
    Varela-Fernandez, Ruben
    Diaz-Tome, Victoria
    Luaces-Rodriguez, Andrea
    Conde-Penedo, Andrea
    Garcia-Otero, Xurxo
    Luzardo-Alvarez, Asteria
    Fernandez-Ferreiro, Anxo
    Otero-Espinar, Francisco J.
    PHARMACEUTICS, 2020, 12 (03)
  • [6] Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill
    Tsai, Danny
    Lipman, Jeffrey
    Roberts, Jason A.
    CURRENT OPINION IN CRITICAL CARE, 2015, 21 (05) : 412 - 420
  • [7] Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis
    Janus, Nicolas
    Launay-Vacher, Vincent
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (06) : 617 - 623
  • [8] Vesicular Drug Delivery Systems: Promising Approaches in Ocular Drug Delivery
    Batur, Eslim
    Ozdemir, Samet
    Durgun, Meltem Ezgi
    Ozsoy, Yildiz
    PHARMACEUTICALS, 2024, 17 (04)
  • [9] Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
    Deng, Rong
    Jin, Feng
    Prabhu, Saileta
    Iyer, Suhasini
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (02) : 141 - 160
  • [10] PHARMACOKINETIC CONSIDERATIONS IN LOCAL-DRUG DELIVERY
    DAEMEN, MJAP
    THIJSSEN, HHW
    STRUYKERBOUDIER, HAJ
    ADVANCED DRUG DELIVERY REVIEWS, 1991, 6 (01) : 1 - 18